Cansino Biologics Stock Profit Margin

688185 Stock   61.23  0.13  0.21%   
Cansino Biologics fundamentals help investors to digest information that contributes to Cansino Biologics' financial success or failures. It also enables traders to predict the movement of Cansino Stock. The fundamental analysis module provides a way to measure Cansino Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cansino Biologics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Cansino Biologics Company Profit Margin Analysis

Cansino Biologics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Profit Margin

 = 

Net Income

Revenue

X

100

More About Profit Margin | All Equity Analysis

Current Cansino Biologics Profit Margin

    
  (0.96) %  
Most of Cansino Biologics' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cansino Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Competition

Based on the latest financial disclosure, Cansino Biologics has a Profit Margin of -0.962%. This is 91.42% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The profit margin for all China stocks is 24.25% lower than that of the firm.

Cansino Profit Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cansino Biologics' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cansino Biologics could also be used in its relative valuation, which is a method of valuing Cansino Biologics by comparing valuation metrics of similar companies.
Cansino Biologics is currently under evaluation in profit margin category among its peers.

Cansino Fundamentals

About Cansino Biologics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cansino Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cansino Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cansino Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Cansino Stock

Cansino Biologics financial ratios help investors to determine whether Cansino Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cansino with respect to the benefits of owning Cansino Biologics security.